Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patient

[News]

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

More... (https://www.news-medical.net/news/20241211/Olaparib-provides-survival-benefits-for-high-risk-BRCA-positive-breast-cancer-patients.aspx)